1. Introduction {#sec0005}
===============

Drugs that are in an amorphous state have significantly different properties from those of their crystalline counterparts. When poorly soluble drugs are in an amorphous state, they have a higher dissolution rate and are more soluble ([@bib0065; @bib0075; @bib0115]). There has been increasing interest in incorporating poorly soluble drugs in medicinal products in their amorphous form, in order to improve their absorption, and hence their bioavailability. However, amorphous materials are not stable and their tendency to crystallize is a challenge when formulations of the amorphous form of the drug are being developed ([@bib0080; @bib0150; @bib0155]). Research efforts have been directed towards improved understanding of the driving force for crystallization in these materials and the conditions that might prolong their physical stability ([@bib0025; @bib0080; @bib0070; @bib0090; @bib0150]). It has been estimated that the amorphous state can be kinetically stable if it is stored at a temperature well below the glass transition temperature (*T*~g~) ([@bib0025; @bib0080; @bib0090]). The *T*~g~ is an intrinsic property of amorphous materials and is therefore often used to indicate their physical stability ([@bib0030]). The physical properties of the materials above and below the *T*~g~ are different and reflect the physical stability of the material ([@bib0025; @bib0060; @bib0080; @bib0150]). The material is considered to exist in a glassy (solid) state below the *T*~g~ and as a supercooled liquid above the *T*~g~. Currently, the mechanistic understanding of the driving force for crystallization above and below the *T*~g~ is sparse and studies of the chemical modifications or formulation strategies that might result in improved performance of amorphous solid dosage forms are warranted.

The stability of amorphous materials upon storage above and below the *T*~g~ has been investigated in several studies, but in each of these only a limited number of compounds has been included ([@bib0025; @bib0060; @bib0080; @bib0150]). These studies linked the crystallization process to molecular mobility, which increases at higher temperatures and hence is higher above the *T*~g~. Thus, materials have a higher tendency to crystallize above than below the *T*~g~. Other studies have found that molecular mobility is not predictive enough to be used as the only determinant for stability in the amorphous state and that other factors such as the configurational entropy([@bib0160]) and enthalpy ([@bib0120]) have significant impact on the stability ([@bib0060; @bib0070]).

In the area of material science, the stability of the amorphous state has been defined as the resistance of glasses to devitrification upon reheating (especially near or somewhat above the *T*~g~) ([@bib0145]). The relationship between glass stability (GS) and glass-forming ability (GFA) has been explored, but only modest relationships have been reported ([@bib0040; @bib0105; @bib0110; @bib0125]). However, a classification system based on the GFA of drug compounds has recently been presented and this system has been related to the GS of the compounds ([@bib0040; @bib0105; @bib0110]). In these studies, the crystallization tendency scheme designed by Taylor and coworkers was used ([@bib0040]). They divided compounds into three classes, depending on how easily the compounds crystallized during a heat-cool-heat cycle. Class I compounds are defined as those that crystallize upon cooling the melt, whereas Class II and Class III compounds form an amorphous material upon cooling the melt. Class II and III compounds are differentiated in that Class II compounds crystallize upon heating the amorphous material, whereas Class III compounds remain amorphous ([@bib0040; @bib0105]). The physical stability of the amorphous form of a drug has been related to thermodynamic factors, and factors such as viscosity and the entropy difference between the melt and the undercooled liquid have been suggested to be driving forces for crystallization ([@bib0055; @bib0095; @bib0140]). However, the thermodynamic properties are difficult to assess below the *T*~g~ and have only been related to physical stability above the *T*~g~ for a limited number of compounds ([@bib0060]).

This work investigated the relationships between the physical stability above and below the *T*~g~ under dry conditions to gain a better understanding of the deviations existing in the relation between storage stability and *T*~g~. A large number of drug compounds were studied to provide a mechanistic understanding of the driving forces behind crystallization. The relationship between the *T*~g~ and the physical stability, and the change in free energy ($\Delta\text{G}_{\text{v}}$) between the melt and the crystalline state and the physical stability after storage was investigated. Further, computational models that predict the physical stability of compounds from their molecular structure were developed to better understand the molecular properties that are important for glass stability.

2. Methods {#sec0010}
==========

2.1. Materials {#sec0015}
--------------

All chemicals were of high purity (98.0--99.9%) and purchased from Sigma--Aldrich (Stockholm, Sweden) except for danazol (Coral drugs IVT, India), itraconazole (Lee Pharma Ltd., India) ezetimibe and ketoconazole (TCR, Toronto, Canada) and bicalutamide, felodipine and linaprazan which were received as a kind gift from AstraZeneca (Mölndal, Sweden), The compounds were selected to provide a wide range of *T*~g~s (225--425 K; [Table 1](#tbl0005){ref-type="table"}) and all were previously identified as compounds with GFA ([@bib0010]).

2.2. Production of the amorphous state {#sec0020}
--------------------------------------

The amorphization of each compound was performed by in situ quenching in a differential scanning calorimetry (DSC) Q2000 (TA) instrument calibrated for temperature and enthalpy using indium. The instrument was equipped with a refrigerated cooling system. The melting point and heat of fusion were determined for each compound using an amount of 1--3 mg in non-hermetic aluminium pans. The compounds were scanned at a heating rate of 10 °C/min under a continuously purged dry nitrogen atmosphere (50 mL/min).

Glass formation was investigated by weighing 1--3 mg of the compound into a non-hermetic pan and heating to about 2 °C above the peak melting temperature. The system was kept isothermal for 2 min to obtain complete melting and was thereafter cooled to −70 °C at a ramp rate of 20 °C/min. The formation of an amorphous state was then investigated by performing a second heat cycle using a heating rate of 20 °C/min immediately after cooling. The production of an amorphous state was indicated by detection of the *T*~g~ upon heating.

2.3. In situ storage in the DSC instrument {#sec0025}
------------------------------------------

After formation of the amorphous materials described in the previous section, an in situ storage study was performed in the DSC instrument. A time frame of 12 h was used and the study was performed twice: 20 °C above and 20 °C below the *T*~g~. The following experimental protocol was used. The sample was:1.heated to about 2 °C above the peak melting temperature, and was thereafter kept isothermal for 2 min to ensure complete melting, followed by cooling to −70 °C at a ramp rate of 20 °C/min to produce the amorphous material;2.heated to 20 °C above the *T*~g~ at 20 °C/min and then cooled to 40 °C below the *T*~g~ at the same heating rate to remove any thermal history;3.heated to the storage temperature (20 °C above or below the *T*~g~) and held at this temperature for 12 h;4.cooled to 40 °C below the *T*~g~ at 20 °C/min;5.heated to 20 °C above melting temperature at a ramp rate of 20 °C/min.

The $\Delta\text{G}_{\text{v}}$ between the liquid and crystalline phases was calculated by the Hoffman equation ([@bib0085]):$$\Delta G_{\text{v}} = \frac{\Delta H_{\text{f}}\left( {T_{\text{m}} - T} \right)T}{T_{\text{m}}^{2}}$$where $\Delta H_{\text{f}}$ is the heat of fusion of the crystalline material, *T*~m~ is the melting temperature, and *T* is the temperature of storage.

3.1. Model development {#sec0030}
----------------------

The computational model was developed using 52 compounds and their corresponding molecular descriptors. The total number of descriptors was 280 which were calculated with the software ADMET Predictor (SimulationsPlus, CA) using molecules represented as structure-data files (sdf). The dataset was divided into training (35 compounds) and test (17 compounds) sets based on the *T*~g~ values and the Class (II or III) of the compounds. A support vector machine (SVM) algorithm was used to build a prediction model, making use of the forward selection procedure. Support vector machine is a supervised learning method which is considered as one of the most successful classification methods ([@bib0135]). The SVM algorithm makes a decision boundary that maximizes the margin between two classes. SVMs also take advantage of nonlinear kernels such as polynomial and Gaussian functions to efficiently perform a non-linear classification by mapping the data into a high dimensional space where it can be linearly separated. The model development procedures started by applying a two-sample *t*-test to the training set for all molecular descriptors (*n* = 280). The variable that achieved the lowest *p*-value was selected for further investigation. This variable was used with the remaining 279 descriptors, one at a time, as inputs into the SVM model. A five-fold cross-validation method was applied to the training set to assess the performance of the SVM model for each added descriptor. This procedure was repeated until no improvement in the performance of the model was noticed.

The performance of the SVM model changes as the values of the SVM parameters change. A leave-one-out cross-validation (LOOCV) was used to tune the parameters. The LOOCV involved dividing the data into two groups: the training and testing sets. Only one observation is used for testing, and the rest of data are used for training. The process is then repeated for all observations (i.e. all compounds) so that every observation is left out in turn from the model development and tested. In this work, the LOOCV was used to assess the performance of the SVM model when its sigma parameter was changed. The sigma value which achieved the lowest classification error was assigned to the SVM model.

3. Results and discussion {#sec0035}
=========================

This study was carried out to gain a better molecular understanding of the stability of amorphous compounds and, hence, only compounds that had previously been identified as good glass-formers were investigated ([@bib0010; @bib0020]). However, compounds from both Class II (where recrystallization occurs upon heating) and Class III (where no recrystallization occurs upon heating) were included. The stability of these compounds was studied under standardized conditions with regard to the *T*~g~. A temperature of 20 °C above and below the *T*~g~ was selected, based on the reasoning that all compounds should have the same *T*~g~/*T* and therefore should have similar prerequisites for crystallization ([Table 1](#tbl0005){ref-type="table"}). The value of *T*~g~/*T* correlates well with the initiation time for crystallization, so this effect was normalized ([@bib0095]).

3.2. Physical stability {#sec0040}
-----------------------

There was no change in the solid state when the compounds were stored below the *T*~g~. Therefore, the physical stability of the compound below the *T*~g~ on the timescale used (12 h) is highly related to the GFA ([@bib0010; @bib0040]). The general trend for Class II compounds when stored above the *T*~g~ was that they rapidly crystallized ([Fig. 1](#fig0005){ref-type="fig"}). Among the 18 Class II compounds, only four remained amorphous after the challenge of elevated temperature. These were tolazamide, cinnarizine, fluorescamine and tamoxifen. All the other Class II compounds crystallized upon storage, as confirmed by the DSC analysis, as there was no sign of a *T*~g~ in the second heating and the enthalpy on melting corresponded to that of the crystalline drug. However, the difference in heat capacity change at the *T*~g~ (Δ*C*~p~) for the four stable compounds was lower after storage than at time zero ([Table 2](#tbl0010){ref-type="table"}). This suggested that the compounds might crystallize upon long term storage and we therefore extended the stability study to 24 h for these substances. After the additional 12 h at the elevated temperature, tamoxifen crystallized and the remaining compounds remained amorphous with further reduced Δ*C*~p~ values ([Table 2](#tbl0010){ref-type="table"}).

The results for the stability of the Class III compounds are presented in [Fig. 2](#fig0010){ref-type="fig"}. Thirty-three of the 34 compounds (97%) remained amorphous after storage, with emtricitabine the only exception. Although a *T*~g~ was detected for nimesulide, fenofibrate and ibuprofen, they behaved like Class II compounds, i.e crystallized upon heating, after storage ([Fig. 3](#fig0015){ref-type="fig"}). Further, the Δ*C*~p~ at the *T*~g~ for these compounds after storage was lower than at time zero ([Table 3](#tbl0015){ref-type="table"}).

This study indicates that the physical state of the material has a clear effect on the crystallization tendency. This was more pronounced for Class II compounds, which all crystallized when in a supercooled liquid state. Therefore, the storage of amorphous Class II drugs with low *T*~g~ values is critical, as the drug will have a high propensity for crystallization.

[Fig. 4](#fig0020){ref-type="fig"} shows the relationship between the *T*~g~ and the physical stability at temperatures above the *T*~g~. The compounds were investigated under similar conditions and, thus, it is expected that their behaviour will reflect their molecular properties. As can be seen over the range of *T*~g~s, which in this study covers 200 K, some compounds with similar *T*~g~s behaved in opposite ways. The *T*~g~ was thus found not to be a factor of importance for the amorphous behaviour and crystallization tendency near the *T*~g~ of a compound. However, it was found that it was mainly compounds from Class III that remained amorphous after 12 h at the elevated temperature, while Class II compounds crystallized. Above the *T*~g~, the material is less viscous (more liquid-like) and the molecular mobility is higher, leading to faster crystallization ([@bib0100; @bib0150]). However, it has been shown that the molecular properties of the drug have a great impact on its crystallization tendency during storage ([@bib0105; @bib0140]). Molecular descriptors reflecting symmetry, electrotopology, polarizability and molecular size have been used to predict stability, and for instance larger drug molecules typically are less prone to crystallize ([@bib0105; @bib0010]).

The relationship between the tendency to crystallize and the $\Delta\text{G}_{\text{v}}$ was investigated to discover the extent to which this thermodynamic property is reflected in the classification system ([Fig. 5](#fig0025){ref-type="fig"} and [Table 1](#tbl0005){ref-type="table"}). No clear trend was found, which is in agreement with other findings in the literature ([@bib0140]). However, it has been predicted earlier that the driving force for nucleation increases with increased $\Delta\text{G}_{\text{v},,}\text{,}$ as shown by increased heat of fusion ([@bib0055]). This relationship did not hold for our data set ([Fig. 5](#fig0025){ref-type="fig"}).

Our results show that Class II compounds crystallized from supercooled liquid when they were kept for a longer time, while Class III compounds were not affected. This clearly distinguishes the behaviour of Class II drugs from that of Class III drugs. The class II compounds did not crystallize from the glassy state, which demonstrate the impact of the physical state on crystallization as well as the inability to relate the crystallization from a supercooled liquid to that from the glassy state.

3.3. Model prediction of physical stability {#sec0045}
-------------------------------------------

Computational prediction of drug properties from the molecular properties at an early stage in drug development is of great interest ([@bib0005; @bib0010; @bib0020]). Since none of the compounds crystallized below *T*~g~, computational modeling was only done on stability data from studies above the *T*~g~. It was found that the descriptor reflecting the Hückel pi atomic charges for carbon atoms had the lowest *p*-value (0.02) when the two-sample *t*-test was performed. Analysis of this descriptor showed that compounds with Hückel pi atomic charge values for carbon atoms greater than 0.5 remain amorphous (17 out of 20) upon storage above the *T*~g~. However, it was not possible to differentiate compounds when this descriptor was less than 0.5. Therefore, other descriptors (i.e. all 280 descriptors except Hückel pi atomic charges for carbon atoms) were gradually added, one at a time, to see if the performance improved. The best performance was seen when the value representing the fraction of aromatic bonds was added to the Hückel pi atomic charges for carbon atoms descriptor. The addition of still more descriptors did not improve the result. Thus, the final SVM model was trained using the whole training data set, represented by these two descriptors, and using a radial basis function (RBF) kernel with sigma = 0.8. The results showed that the proposed SVM-based prediction model was able to correctly classify the stability of the compounds above the *T*~g~ for 83% of the training set, and 82% of the test set, as shown in [Fig. 6](#fig0030){ref-type="fig"}. The good classification accuracy shows that the SVM decision boundary (i.e the red line in [Fig. 6](#fig0030){ref-type="fig"}) well-separated compounds that were amorphous after the stability study (green circle in [Fig. 6](#fig0030){ref-type="fig"}) and crystalline after the stability study (blue triangular in [Fig. 6](#fig0030){ref-type="fig"}). The Hückel and aromaticity parameters affect the molecular conformation, ([@bib0015; @bib0130] and the molecular conformation affects the crystallization of the molecule ([@bib0035; @bib0045; @bib0050]). Compounds with more aromatic bonds seem to crystallize faster at storage conditions above the *T*~g~. Some compounds with high Hückel values are lacking aromatic structures and have a lower crystallization propensity. However, our model identified two important parameters that can classify the tendencies of compounds to crystallize from the supercooled liquid. Other factors that we have identified earlier, such as the molecular weight, size and shape of the molecule, are related to the basic classification of the compounds into Class II or Class III.

These results indicate that the chemical structure of the compound significantly impacts on its crystallization tendencies and can be used, for example, to determine the stability of two compounds with similar *T*~g~s without the need for experimental determination of, for example, the class.

4. Conclusion {#sec0050}
=============

This study investigated the crystallization tendency and physical stability upon storage of a series of drugs as a function of temperature. All the compounds were stored at 20 K below and above their *T*~g~s to explore their inherent stability and it was revealed that the GFA can be used to predict the physical stability. It was found that Class III compounds remained amorphous under the studied dry conditions. In contrast, the majority of Class II compounds crystallized when stored at 20 K above the *T*~g~ but remained amorphous when stored at 20 K below the *T*~g~. The *T*~g~ was poorly correlated to the physical stability under the studied conditions, further strengthening previous indications that molecular properties has a considerable impact on both the GFA and the GS. For Class II compounds, the physical state influenced the crystallization tendency; crystallization was faster from an undercooled liquid state than from a glassy state. The developed computational model predicted the stability of the compounds above *T*~g~ well, using two chemical descriptors: Hückel pi atomic charges for carbon atoms and aromaticity. To conclude, this study supports previous findings that the molecular structure of a compound holds key information about the GFA and stability of the amorphous state and can be used to better understand, and also to predict, these complex properties.
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![Stability results for Class II compounds; *n* = 18; stored above the *T*~g~.](gr1){#fig0005}

![Stability results for Class III compounds; *n* = 34; stored above the *T*~g~.](gr2){#fig0010}
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![Relationship between the *T*~g~ and the solid-state type (amorphous/crystalline) after the stability study for Class II (blue star) and Class III (black circle) compounds.](gr4){#fig0020}

![Relationship between the free energy change and the stability result (amorphous/crystalline) after storage above the *T*~g~ for Class II (blue star) and Class III (black circle) compounds.](gr5){#fig0025}

![Prediction of glass stability using the support vector machine algorithm for all the study compounds that were amorphous after the stability study (green circle) and crystalline after the stability study (blue triangular). The crosses indicate the test set. Red line indicates the boundary generated by the SVM model.](gr6){#fig0030}

###### 

Compounds used in the study with their molecular weight (MW), melting temperature (*T*~m~), heat of fusion (ΔH), glass transition temperature (*T*~g~), temperature for the stability test above *T*~g~ (*T*~above~ = *T*~g~ + 20), change in free energy (ΔG) between the supercooled liquid and the crystalline state at T, and result of the stability test (no = crystalline and yes = amorphous). Pi_AQc = sum of absolute values of Hückel pi atomic charges on C atoms; F_AromB = number of aromatic bonds as a fraction of total bonds; TR = training set; TS = test set.

  Compound                                          Class   MW (g/mole)   *T*~m~ (K)   ΔH kJ/mole   *T*~g~ (K)   *T*~above~ (K)   *T*~g~/*T*~above~   ΔG (kJ/mol)   Stable above *T*~g~[a](#tblfn0005){ref-type="table-fn"}   Pi_AQc   F_AromB   TR/TS
  ------------------------------------------------- ------- ------------- ------------ ------------ ------------ ---------------- ------------------- ------------- --------------------------------------------------------- -------- --------- -------
  Acetaminophen                                     II      151.2         443          29           299          319              0.94                5.9           No                                                        0.48     0.55      TR
  Celecoxib                                         II      318.4         436          32           331          351              0.94                5.1           No                                                        0.45     0.61      TR
  Danazol                                           II      337.5         500          36           352          372              0.95                6.8           No                                                        0.15     0.17      TR
  Estradiol                                         II      22.4          451          2            358          378              0.95                0.3           No                                                        0.22     0.26      TR
  Nifedipine                                        II      346.3         446          39           320          340              0.94                7.0           No                                                        1.00     0.23      TR
  Orlistat                                          II      495.8         316          56           228          248              0.92                9.4           No                                                        0.72     0         TR
  Pimozide                                          II      461.6         492          50           335          355              0.94                10.1          No                                                        0.53     0.58      TR
  Tamoxifen                                         II      371.5         371          56           263          283              0.93                10.2          Yes                                                       0.24     0.60      TR
  Tenofovir                                         II      28.2          552          3            416          436              0.95                1.2           No                                                        0.29     0.50      TR
  Testosterone                                      II      288.4         426          26           315          335              0.94                4.4           No                                                        0.40     0         TR
  Tinidazole                                        II      247.3         289          36           266          286              0.93                0.4           No                                                        0.20     0.31      TR
  Tolazamide                                        II      311.4         445          41           297          317              0.94                8.3           Yes                                                       0.40     0.27      TR
  Aripiprazole                                      II      448.4         517          48           363          383              0.95                9.2           No                                                        0.94     0.36      TS
  Bicalutamide                                      II      430.4         465          51           323          343              0.94                9.9           No                                                        0.82     0.40      TS
  Cinnarizine                                       II      368.5         394          43           280          300              0.93                7.7           Yes                                                       0.03     0.58      TS
  Clemastine                                        II      343.9         451          48           308          328              0.94                9.6           No                                                        0.09     0.46      TS
  Fluorescamine                                     II      278.3         426          28           299          319              0.94                5.7           Yes                                                       0.83     0.50      TS
  Flurbiprofen                                      II      244.3         388          28           270          290              0.93                5.4           No                                                        0.38     0.63      TS
  Acemetacin                                        III     415.8         421          48           310          330              0.94                8.1           Yes                                                       1.34     0.52      TR
  Budesonide                                        III     430.5         530          39           368          388              0.95                7.6           Yes                                                       0.73     0         TR
  Captopril                                         III     217.3         380          29           277          297              0.93                4.9           Yes                                                       0.46     0         TR
  Carvedilol                                        III     406.5         390          53           315          335              0.94                6.4           Yes                                                       0.83     0.64      TR
  Chloramphenicol                                   III     323.1         425          4            304          324              0.94                0.7           Yes                                                       0.39     0.30      TR
  Chlorhexidine                                     III     505.5         408          43           336          356              0.94                4.7           Yes                                                       0.86     0.34      TR
  Clotrimazole                                      III     344.9         418          35           303          323              0.94                6.1           Yes                                                       0.29     0.82      TR
  Emtricitabine                                     III     247.2         426          27           344          364              0.95                3.4           No                                                        0.41     0.35      TR
  Ezetimibe                                         III     409.4         437          40           338          358              0.94                6.0           Yes                                                       0.74     0.55      TR
  Felodipine                                        III     384.3         420          34           318          338              0.94                5.3           Yes                                                       0.93     0.23      TR
  Hydrocortisone                                    III     362.5         497          45           359          379              0.95                8.1           Yes                                                       0.69     0         TR
  Ibuprofen[b](#tblfn0010){ref-type="table-fn"}     III     206.3         350          27           228          248              0.92                5.5           Yes                                                       0.30     0.40      TR
  Indomethacin                                      III     356.7         434          42           318          338              0.94                7.2           Yes                                                       1.10     0.59      TR
  Itraconazole                                      III     705.7         441          65           331          351              0.94                10.6          Yes                                                       1.02     0.51      TR
  Ketoprofen                                        III     254.3         368          31           270          290              0.93                5.2           Yes                                                       0.72     0.60      TR
  Linaprazan                                        III     366.5         519          55           373          393              0.95                10.1          Yes                                                       0.73     0.55      TR
  Metolazone                                        III     365.8         539          36           382          402              0.95                6.8           Yes                                                       0.87     0.46      TR
  Nizatidine                                        III     331.5         406          45           286          306              0.93                8.4           Yes                                                       0.50     0.24      TR
  Physostigmine                                     III     275.4         377          32           293          313              0.94                4.5           Yes                                                       0.47     0.27      TR
  Simvastatin                                       III     418.8         412          29           309          329              0.94                4.6           Yes                                                       0.51     0         TR
  Spironolactone                                    III     416.6         486          24           364          384              0.95                4.0           Yes                                                       0.90     0         TR
  Sulindac                                          III     356.4         460          32           348          368              0.95                5.2           Yes                                                       0.74     0.44      TR
  Zolmitriptan                                      III     287.4         410          34           322          342              0.94                4.7           Yes                                                       0.56     0.43      TR
  Bucindolol                                        III     363.5         459          38           356          376              0.95                5.6           Yes                                                       0.79     0.55      TS
  Fenofibrate[b](#tblfn0010){ref-type="table-fn"}   III     360.8         354          35           256          276              0.93                6.1           Yes                                                       0.91     0.46      TS
  Glafenine                                         III     372.8         437          43           337          357              0.94                6.4           Yes                                                       0.90     0.61      TS
  Glibenclamide                                     III     494           445          51           333          353              0.94                8.3           Yes                                                       0.81     0.34      TS
  Hydrochlorothiazide                               III     297.7         536          34           391          411              0.95                6.1           Yes                                                       0.61     0.33      TS
  Hydroflumethiazide                                III     297.9         542          39           373          393              0.95                7.9           Yes                                                       0.48     0.29      TS
  Isradipine                                        III     371.4         432          34           316          336              0.94                5.8           Yes                                                       0.86     0.34      TS
  Ketoconazole                                      III     531.4         423          54           318          338              0.94                8.7           Yes                                                       0.90     0.43      TS
  Nandrolone                                        III     274.4         397          21           310          330              0.94                2.9           Yes                                                       0.41     0         TS
  Nimesulide[b](#tblfn0010){ref-type="table-fn"}    III     308.3         423          36           296          316              0.94                6.7           Yes                                                       0.43     0.55      TS
  Warfarin                                          III     308.3         435          45           345          365              0.95                6.0           Yes                                                       1.03     0.68      TS

No = not amorphous after the stability study; yes = amorphous after the stability study.

Behaved like a Class II drug after the stability study.

###### 

Heat capacity change at *T*~g~ (Δ*C*~p~) (J g °C^−1^) for Class II compounds analysed at time 0 and after 12 and 24 h′ storage.

  Time (h)   Cinnarizine   Fluorescamine   Tamoxifen   Tolazamide
  ---------- ------------- --------------- ----------- ------------
  0          0.57          0.48            0.49        0.55
  12         0.54          0.42            0.46        0.22
  24         0.33          0.27            --          0.22

###### 

Heat capacity change at *T*~g~ (Δ*C*~p~) (J g °C^−1^) at time 0 and after 12 h′ storage for Class III compounds that behaved like Class II compounds after storage.

  Time (h)   Ibuprofen   Fenofibrate   Nimesulide
  ---------- ----------- ------------- ------------
  0          0.43        0.48          0.50
  12         0.43        0.18          0.41
